There are no such explicit recommendations in these guidelines for T2DM individuals without established ASCVD and having multiple recognized risk factors, such as hypertension, dyslipidemia, obesity, smoking, and family history of diabetes, that are known to substantially increase the risk of CV complications and worsen outcomes, but SGLT-2 and DPP-IV inhibitors are listed as the preferred oral antidiabetic drugs (OADs) as an add-on to metformin generally wherever feasible. This evidence concerns the gene SLC5A2 and diabetes mellitus.